Johnson & Johnson's Famous Three-Legged Stool Was Never Standing on Three Legs.

For decades, the line you heard about Johnson & Johnson was the same: a company that stands on a three-legged stool - pharmaceuticals, medical devices, and the consumer brands in your bathroom cabinet. The image did a lot of work. Three legs feel sturdy, balanced, hard to tip over. Lose your footing in drugs and the Band-Aids hold you up. It's a beautiful piece of corporate folklore. It was also never true.

The official story is that J&J was a diversified health giant balanced across three equal businesses, and that in 2021 it made the bold decision to set one of them free. The real story is quieter and more revealing: the consumer leg was always a stub, the smallest and lowest-margin part of the company, and the split was less a strategic rebalancing than a triage - shedding a slow-growth business so the fast-growth ones could be valued on their own terms. Read the filings instead of the folklore and the stool falls over on its own.

The leg that was always shorter than the others

Start with the numbers J&J reported to the SEC, not the metaphor it reported to the public. In fiscal 2021, pharmaceuticals generated about 55.5% of revenue, medical devices about 28.9%, and consumer health only about 15.6%.³ That is not a stool. A stool with one leg a third the height of the others doesn't stand - it leans, and it has been leaning that way for a long time. The three-segment structure shows up in J&J's primary filings going back at least to fiscal 2002,² and consumer was the runt in all of them. The framing survived not because it was accurate but because it was reassuring.

Why you cut the smallest, slowest leg first

If the legs were never equal, why keep the metaphor and the business for so long - and then cut it in 2021? The mechanism is about valuation, not balance. A drug pipeline and a portfolio of toothpaste and baby shampoo are priced by entirely different markets: one on innovation and patents, the other on shelf stability and brand. Bolt them together and investors split the difference, applying a blended multiple that flatters neither. The smallest, slowest-growing leg drags the multiple on the largest, fastest one. So J&J announced on November 12, 2021 that it would separate the consumer business, framing it as a way to create two companies 'better positioned to deliver improved health outcomes' with more targeted strategies.¹ The shareholder FAQ filed with the separation put the logic even more plainly: make each company 'more agile, focused and competitive.'⁶ Notice what that language is not. It is not the language of rebalancing a portfolio. It is the language of unloading one.

The execution came in two distinct moves that press accounts often blur into one. First the IPO: on May 8, 2023, the consumer business - now named Kenvue - sold about 199 million shares at $22.00 each, raising roughly $4.2 billion in net proceeds while still a J&J subsidiary.⁴ Then the real separation, an exchange offer that let J&J shareholders swap their J&J stock for Kenvue stock. It closed in August 2023, oversubscribed more than fourfold, and moved about 80.1% of Kenvue's outstanding shares off J&J's books.⁵ But not all of them. J&J kept 9.5%.⁵ The 'clean break' wasn't clean - it was a managed exit with a stake retained, the parent quietly holding a residual claim on the child it had just sent into the world.

Didn't the spin-off unlock a hidden discount?

The fair objection is that this is exactly how value gets unlocked - that conglomerates trade at a discount, and prying the consumer business loose let the market finally price J&J's drug engine on its own. It's a clean theory, and the market didn't immediately buy it. When the separation was announced in November 2021, the stock moved only modestly higher; an analyst at Cantor Fitzgerald noted investors were 'not fully convinced yet of the standalone earnings potential of both companies.'⁸ If the conglomerate discount were large and obvious, the announcement should have produced a sharp re-rating. It produced a shrug. That doesn't prove the logic was wrong - focus genuinely helps over time - but it punctures the tidy story that J&J had been sitting on locked-up value that one press release released. The move was defensible. It was not magic.

When the stool becomes a peg

Here is the tell that the three-legged identity is gone for good. After Kenvue, J&J ran just two segments. Then, on October 14, 2025, it announced it would separate its Orthopaedics business as a standalone DePuy Synthes within 18 to 24 months - a business that did roughly $9.2 billion in FY2024 sales, about 10% of total revenue - explicitly to focus its remaining medical-technology arm on 'higher-growth and higher-margin markets.'⁷ Read the two separations together and the strategy is unmistakable. This is not a company pruning to stay balanced. It is a company peeling away everything that isn't a fast-growing, high-margin drug or device, one leg at a time. The stool isn't being rebuilt sturdier. It's being whittled down to a peg - a focused pharma play with a deliberately shrinking medtech residue beside it.

The three-legged stool was a good story that outlived the truth it was supposed to describe. J&J never stood on three equal legs; it stood on a tall pharma leg, a shorter device leg, and a stub it called consumer for the comfort of the metaphor. The Kenvue split didn't break a balanced company - it admitted the balance was never there. And the orthopedics spin-off that followed confirms the direction: not toward sturdiness, but toward focus. The most quoted idea about Johnson & Johnson turned out to be the one the company was quietly dismantling all along.